Co-Delivery of Doxorubicin and PEGylated C16-Ceramide by Nanoliposomes for Enhanced Therapy Against Multidrug Resistance

References

• Holohan C , Van SchaeybroeckS , LongleyDB , JohnstonPG . Cancer drug resistance: an evolving paradigm . Nat. Rev. Cancer13 ( 10 ), 714 – 726 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Dean M , FojoT , BatesS . Tumour stem cells and drug resistance . Nat. Rev. Cancer5 ( 4 ), 275 – 284 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Shapira A , LivneyYD , BroxtermanHJ , AssarafYG . Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance . Drug Resist. Updat.14 ( 3 ), 150 – 163 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Gao J , FengSS , GuoY . Nanomedicine for treatment of cancer stem cells . Nanomedicine (Lond.)9 ( 2 ), 181 – 184 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Stover TC , KimYS , LoweTL , KesterM . Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug . Biomaterials29 ( 3 ), 359 – 369 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Liu YY , HanTY , GiulianoAE , CabotMC . Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers doxorubicin resistance in human breast cancer cells . J. Biol. Chem.274 ( 2 ), 1140 – 1146 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Lavie Y , CaoH , BurstenSL , GiulianoAE , CabotMC . Accumulation of glucosylceramides in multidrug-resistant cancer cells . J. Biol. Chem.271 ( 32 ), 19530 – 19536 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Lucci A , HanTY , LiuYY , GiulianoAE , CabotMC . Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics . Int. J. Oncol.15 ( 3 ), 541 – 546 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Rath G , SchneiderC , LangloisBet al. De novo ceramide synthesis is responsible for the anti-tumor properties of camptothecin and doxorubicin in follicular thyroid carcinoma . Int. J. Biochem. Cell Biol.41 ( 5 ), 1165 – 1172 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Dumitru CA , CarpinteiroA , TrarbachT , HenggeUR , GulbinsE . Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms . Apoptosis12 ( 8 ), 1533 – 1541 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Liu YY , YuJY , YinDet al. A role for ceramide in driving cancer cell resistance to doxorubicin . FASEB J.22 ( 7 ), 2541 – 2551 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• van Vlerken LE , DuanZ , SeidenMV , AmijiMM . Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer . Cancer Res.67 ( 10 ), 4843 – 4850 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Gouazé V , YuJY , BleicherRJet al. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy . Mol. Cancer Ther.3 ( 5 ), 633 – 639 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Liu YY , HanTY , GiulianoAE , CabotMC . Ceramide glycosylation potentiates cellular multidrug resistance . FASEB J.15 ( 3 ), 719 – 730 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• van Lummel M , van BlitterswijkWJ , VinkSRet al. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors . FASEB J.25 ( 1 ), 280 – 289 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Veldman RJ , KoningGA , van HellAet al. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin . J. Pharmacol. Exp. Ther.315 ( 2 ), 704 – 710 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Pedrosa LR , van HellA , SüssRet al. Improving intracellular doxorubicin delivery through nanoliposomes equipped with selective tumor cell membrane permeabilizing short-chain sphingolipids . Pharm. Res.30 ( 7 ), 1883 – 1895 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Senchenkov A , LitvakDA , CabotMC . Targeting ceramide metabolism – a strategy for overcoming drug resistance . J. Natl Cancer Inst.93 ( 5 ), 347 – 357 ( 2001 ).
   PubMedGoogle Scholar
• Devalapally H , DuanZ , SeidenMV , AmijiMM . Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles . Clin. Cancer Res.14 ( 10 ), 3193 – 3203 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Devalapally H , DuanZ , SeidenMV , AmijiMM . Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer . Int. J. Cancer121 ( 8 ), 1830 – 1838 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Fonseca NA , Gomes-da-SilvaLC , MouraV , SimõesS , MoreiraJN . Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination . J. Control. Release196 , 122 – 131 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Abraham SA , McKenzieC , MasinDet al. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and ph gradient loading . Clin. Cancer Res.10 ( 2 ), 728 – 738 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Torchilin VP . Recent advances with liposomes as pharmaceutical carriers . Nat. Rev. Drug Discov.4 ( 2 ), 145 – 160 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Win KY , FengSS . Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs . Biomaterials26 ( 15 ), 2713 – 2722 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Zhang S , LiJ , LykotrafitisG , BaoG , SureshS . Size-dependent endocytosis of nanoparticles . Adv. Mater.21 , 419 – 424 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Decuzzi P , FerrariM . The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles . Biomaterials28 ( 18 ), 2915 – 2922 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Veiga MP , ArrondoJL , GoñiFM , AlonsoA . Ceramides in phospholipid membranes: effects on bilayer stability and transition to nonlamellar phases . Biophys. J.76 ( 1 ), 342 – 350 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Khazanov E , PrievA , ShillemansJP , BarenholzY . Physicochemical and biological characterization of ceramide-containing liposomes: paving the way to ceramide therapeutic application . Langmuir24 ( 13 ), 6965 – 6980 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Han L , MiyasakaK , TerasakiO , CheS . Evolution of packing parameters in the structural changes of silica mesoporous crystals: cage-type, 2D cylindrical, bicontinuous diamond and gyroid, and lamellar . J. Am. Chem. Soc.133 ( 30 ), 11524 – 11533 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Kumar VV . Complementary molecular shapes and additivity of the packing parameter of lipids . Proc. Natl Acad. Sci. USA88 ( 2 ), 444 – 448 ( 1991 ).
   PubMed Web of Science ®Google Scholar
• Wheeler JJ , PalmerL , OssanlouMet al. Stabilized plasmid-lipid particles: construction and characterization . Gene Ther.6 ( 2 ), 271 – 281 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Zhang YP , SekirovL , SaravolacEGet al. Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties . Gene Ther.6 ( 8 ), 1438 – 1447 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Feng SS . Interpretation of mechanochemical properties of lipid monolayers at the air-water or oil-water interface and bilayer vesicles from equation of state or pressure-area measurement . Langmuir15 ( 4 ), 998 – 1010 ( 1999 ).
   Web of Science ®Google Scholar
• Feng SS , MacDonaldRC . Effects of chain unsaturation on equation of state for monolayers at the air-water interface . Biophys. J.69 ( 2 ), 460 – 469 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Cao N , FengSS . Doxorubicin conjugated to d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS): in vitro cytotoxicity, in vivo pharmacokinetics and biodistribution . Biomaterials29 ( 28 ), 3856 – 3865 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Anbharasi V , CaoN , FengSS . Targeted delivery of doxorubicin conjugated to folic acid and d-α-tocopheryl polyethylene glycol succinate (TPGS) . J. Biomed. Mat. Res. A94 ( 3 ), 730 – 743 ( 2010 ).
   PubMedGoogle Scholar
• Gao J , XiaY , ChenHet al. Polymer-lipid hybrid nanoparticles conjugated with anti-EGF receptor antibody for targeted drug delivery to hepatocellular carcinoma . Nanomedicine (Lond.)9 ( 2 ), 279 – 293 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Sapra P , TyagiP , AllenTM . Ligand-targeted liposomes for cancer treatment . Curr. Drug Deliv.2 ( 4 ), 369 – 381 ( 2005 ).
   PubMedGoogle Scholar
• Sapra P , AllenTM . Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes . Clin. Cancer Res.10 ( 7 ), 2530 – 2537 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Stewart JC . Colorimetric determination of phospholipids with ammonium ferrothiocyanate . Anal. Biochem.104 ( 1 ), 10 – 14 ( 1980 ).
   PubMed Web of Science ®Google Scholar
• Gao J , FengSS , GuoY . Nanomedicine against multidrug resistance in cancer treatment . Nanomedicine (Lond.)7 ( 4 ), 465 – 468 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lasic DD , WoodleMC , MartinFJ , ValentincicT . Phase behavior of ‘stealth-lipid’ decithin mixtures . Period Biol.93 , 9287 – 9290 ( 1991 ).
   Web of Science ®Google Scholar
• Watters RJ , KesterM , TranMA , LoughranTPJr , LiuX . Development and use of ceramide nanoliposomes in cancer . Methods Enzymol.508 , 89 – 108 ( 2012 ).
   PubMed Web of Science ®Google Scholar